NO761009L - - Google Patents
Info
- Publication number
- NO761009L NO761009L NO761009A NO761009A NO761009L NO 761009 L NO761009 L NO 761009L NO 761009 A NO761009 A NO 761009A NO 761009 A NO761009 A NO 761009A NO 761009 L NO761009 L NO 761009L
- Authority
- NO
- Norway
- Prior art keywords
- hydroxy
- quinoline
- compounds
- tetrazol
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 52
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 9
- RBNLMAXLHADNEU-UHFFFAOYSA-N 4-oxo-1h-quinoline-3-carbonitrile Chemical class C1=CC=C2C(=O)C(C#N)=CNC2=C1 RBNLMAXLHADNEU-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- -1 tetrazole compounds Chemical class 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 3
- YDPLDMLRERBXAV-UHFFFAOYSA-N aluminum;triazide Chemical compound [Al+3].[N-]=[N+]=[N-].[N-]=[N+]=[N-].[N-]=[N+]=[N-] YDPLDMLRERBXAV-UHFFFAOYSA-N 0.000 claims description 2
- BIMDWYPWZNTWLE-UHFFFAOYSA-N chembl3304057 Chemical compound C1=NC2=CC=CC=C2C(O)=C1C1=NN=NN1 BIMDWYPWZNTWLE-UHFFFAOYSA-N 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000005422 alkyl sulfonamido group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- OKFKQUTVVBIIEZ-UHFFFAOYSA-N chembl3228175 Chemical group ClC1=CC=CC(C2=O)=C1NC=C2C1=NN=NN1 OKFKQUTVVBIIEZ-UHFFFAOYSA-N 0.000 claims 2
- ACKJRXARXHCHEV-UHFFFAOYSA-N chembl3303816 Chemical compound C=1N=C2C(OC)=CC=CC2=C(O)C=1C1=NN=NN1 ACKJRXARXHCHEV-UHFFFAOYSA-N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 239000012442 inert solvent Substances 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- MLIREBYILWEBDM-UHFFFAOYSA-M 2-cyanoacetate Chemical compound [O-]C(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-M 0.000 claims 1
- UFCSVGOSWWHTES-UHFFFAOYSA-N 8-chloro-4-oxo-1h-quinoline-3-carbonitrile Chemical group N1C=C(C#N)C(=O)C2=C1C(Cl)=CC=C2 UFCSVGOSWWHTES-UHFFFAOYSA-N 0.000 claims 1
- MRVAPQVMJIMWNH-UHFFFAOYSA-N 8-methyl-4-oxo-1h-quinoline-3-carbonitrile Chemical compound N1C=C(C#N)C(=O)C2=C1C(C)=CC=C2 MRVAPQVMJIMWNH-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- FKDXLSINWVFXIC-UHFFFAOYSA-N chembl3304090 Chemical compound C1=NC2=CC=C(F)C=C2C(O)=C1C1=NN=NN1 FKDXLSINWVFXIC-UHFFFAOYSA-N 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
- 239000003380 propellant Substances 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 229940124630 bronchodilator Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 108010058846 Ovalbumin Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 208000003455 anaphylaxis Diseases 0.000 description 4
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 150000003536 tetrazoles Chemical class 0.000 description 4
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000001045 blue dye Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- KBHILCCHUNDPIU-UHFFFAOYSA-N 8-bromo-4-oxo-1h-quinoline-3-carbonitrile Chemical compound C1=CC=C2C(O)=C(C#N)C=NC2=C1Br KBHILCCHUNDPIU-UHFFFAOYSA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000460 chlorine Chemical group 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Chemical group 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- KTMGNAIGXYODKQ-UHFFFAOYSA-N ethyl 2-cyano-3-ethoxyprop-2-enoate Chemical compound CCOC=C(C#N)C(=O)OCC KTMGNAIGXYODKQ-UHFFFAOYSA-N 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960001268 isoetarine Drugs 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/564,557 US4035368A (en) | 1975-04-02 | 1975-04-02 | Substituted 3-(1H-tetrazol-5-yl)-quinoline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO761009L true NO761009L (de) | 1976-10-05 |
Family
ID=24254947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO761009A NO761009L (de) | 1975-04-02 | 1976-03-23 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4035368A (de) |
| JP (1) | JPS51122076A (de) |
| AU (1) | AU1259476A (de) |
| BE (1) | BE840288A (de) |
| DE (1) | DE2614089A1 (de) |
| DK (1) | DK126776A (de) |
| IL (1) | IL49328A0 (de) |
| NL (1) | NL7602993A (de) |
| NO (1) | NO761009L (de) |
| OA (1) | OA05295A (de) |
| SE (1) | SE7603543L (de) |
| ZA (1) | ZA761253B (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4252945A (en) * | 1979-07-11 | 1981-02-24 | E. R. Squibb & Sons, Inc. | Process for preparing pyrazolo[1,5-c]-quinazoline derivatives and novel intermediates |
| US4419357A (en) * | 1982-01-18 | 1983-12-06 | The Dow Chemical Company | 3-(1H-Tetrazol-5-yl)-4(3H)-quinazolinones |
| US4496569A (en) * | 1983-03-25 | 1985-01-29 | The Dow Chemical Company | Antiallergic (1H-tetrazol-5-yl)tetrazolo[1,5-a]quinolines and derivatives thereof |
| US4735948A (en) * | 1983-03-25 | 1988-04-05 | Merrell Dow Pharmaceuticals Inc. | (1H-tetrazol-5-yl)-2(1H)-quinolinones and-naphthyridones and antiallergic use thereof |
| PT79031B (en) * | 1983-08-20 | 1986-08-22 | Boots Co Plc | Therapeutic agents |
| US5731440A (en) * | 1994-03-01 | 1998-03-24 | Ishihara Sangyo Kaisha Ltd. | Intermediates for producing 5,7-dichloro-4-hydroxyquinoline |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2719848A (en) * | 1955-06-07 | 1955-10-04 | Charles F Geschickter | 4-(dimethylaminoethylamino)-6-methoxy quinoline and salts thereof |
| US3178348A (en) * | 1961-02-08 | 1965-04-13 | Norwich Pharma Co | Hypotensive quinolines |
| NL140730B (nl) * | 1963-09-27 | 1974-01-15 | Fisons Pharmaceuticals Ltd | Werkwijze voor de bereiding van gesubstitueerde chromoncabonzuur-2-derivaten met remmende werking op anafylactische reacties. |
| BE759292A (fr) * | 1969-11-27 | 1971-05-24 | Allen & Hanburys Ltd | Derives de xanthone, leur preparation et leur emploi |
| GB1296469A (de) * | 1970-02-05 | 1972-11-15 |
-
1975
- 1975-04-02 US US05/564,557 patent/US4035368A/en not_active Expired - Lifetime
-
1976
- 1976-03-02 ZA ZA761253A patent/ZA761253B/xx unknown
- 1976-03-22 NL NL7602993A patent/NL7602993A/xx unknown
- 1976-03-23 SE SE7603543A patent/SE7603543L/xx unknown
- 1976-03-23 NO NO761009A patent/NO761009L/no unknown
- 1976-03-23 DK DK126776A patent/DK126776A/da unknown
- 1976-03-31 JP JP51035916A patent/JPS51122076A/ja active Pending
- 1976-04-01 IL IL49328A patent/IL49328A0/xx unknown
- 1976-04-01 DE DE19762614089 patent/DE2614089A1/de active Pending
- 1976-04-01 OA OA55790A patent/OA05295A/xx unknown
- 1976-04-01 BE BE165770A patent/BE840288A/xx unknown
- 1976-04-02 AU AU12594/76A patent/AU1259476A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| NL7602993A (nl) | 1976-10-05 |
| BE840288A (fr) | 1976-10-01 |
| JPS51122076A (en) | 1976-10-25 |
| SE7603543L (sv) | 1976-10-03 |
| DE2614089A1 (de) | 1976-10-14 |
| AU1259476A (en) | 1977-10-06 |
| DK126776A (da) | 1976-10-03 |
| OA05295A (fr) | 1981-02-28 |
| US4035368A (en) | 1977-07-12 |
| IL49328A0 (en) | 1976-06-30 |
| ZA761253B (en) | 1977-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8846709B2 (en) | 7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1H-imidazo[4,5-C]quinoline derivatives | |
| Buckle et al. | 4-Hydroxy-3-nitro-2-quinolones and related compounds as inhibitors of allergic reactions | |
| US5455252A (en) | Optionally substituted 6,8-quinolines | |
| JPS6393765A (ja) | 置換されたフエニルスルホンアミド類 | |
| CA2141692C (en) | Prodrugs of imidazole carboxylic acids as angiotensin ii receptor antagonists | |
| DK166582B1 (da) | Pyridylmethoxyderivater og farmaceutisk acceptable salte og lethydrolyserbare estre deraf, deres fremstilling og farmaceutisk praeparat indeholdende samme | |
| WO2016197589A1 (zh) | 一种噻吩并嘧啶类衍生物及其制备方法和应用 | |
| JPH1059914A (ja) | ヘテロ−結合フエニルグリシノールアミド | |
| US20110045100A1 (en) | Antimalarial Quinolines and Methods of Use Thereof | |
| NO761009L (de) | ||
| EP0053407A2 (de) | Imidazolylphenylamidine, Verfahren zur Herstellung, ihre pharmazeutische Anwendung und Zwischenprodukte für ihre Herstellung | |
| Snyder et al. | Synthesis of 4-Hydroxyquinolines. VIII. Some Halogen Containing 4-Aminoquinoline Derivatives1 | |
| US4147694A (en) | 8-(1H-Tetrazol-5-yl-carbamoyl)quinoline compounds | |
| KR900003650B1 (ko) | (1h-테트라졸-5-일)-2(1h)-퀴놀리논, 나프티리디논 및 그의 제조방법 | |
| US4419357A (en) | 3-(1H-Tetrazol-5-yl)-4(3H)-quinazolinones | |
| Roblin Jr et al. | Chemotherapy. I. Substituted Sulfanilamidopyridines1 | |
| CA1117112A (en) | Pyrido¬1,2-a|pyrimidine-3-n-(1h-tetrazol-5-yl| carboxamide derivatives | |
| KR900002248B1 (ko) | 치환된 1,2,3-트리아지노[4',5':4,5] 티에노[2,3-b]퀴놀린-4(3H)-온 및 그의 제조방법 | |
| Stephen et al. | 192. Tetrahydroacridones and related compounds as antimalarials | |
| US4186201A (en) | Methods of using 8(tetrazol-5-ylcarbamoyl)isoquinoline compounds | |
| CH616679A5 (en) | Process for the preparation of N-(5-tetrazolyl)-1-oxo-1H-pyrimido[1,2-a]quinoline-2-carboxamides | |
| US4018780A (en) | [1]Benzothieno[3,2-f]quinolinecarboxylic acids | |
| NL192040C (nl) | Carbostyrilverbindingen en preparaat dat een dergelijke verbinding bevat. | |
| US4567193A (en) | 2-(Formylamino)-N-(1H-tetrazol-5-yl)benzamide and use as anti-allergics | |
| DK158725B (da) | N-phenyl-oxamsyrederivater og farmaceutiske praeparater indeholdende disse |